Cargando…
Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease
A series of novel ligustrazine derivatives 8a–r were designed, synthesized, and evaluated as multi-targeted inhibitors for anti-Alzheimer’s disease (AD) drug discovery. The results showed that most of them exhibited a potent ability to inhibit both ChEs, with a high selectivity towards AChE. In part...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222487/ https://www.ncbi.nlm.nih.gov/pubmed/30301153 http://dx.doi.org/10.3390/molecules23102540 |
_version_ | 1783369216691273728 |
---|---|
author | Wu, Wenhao Liang, Xintong Xie, Guoquan Chen, Langdi Liu, Weixiong Luo, Guolin Zhang, Peiquan Yu, Lihong Zheng, Xuehua Ji, Hong Zhang, Chao Yi, Wei |
author_facet | Wu, Wenhao Liang, Xintong Xie, Guoquan Chen, Langdi Liu, Weixiong Luo, Guolin Zhang, Peiquan Yu, Lihong Zheng, Xuehua Ji, Hong Zhang, Chao Yi, Wei |
author_sort | Wu, Wenhao |
collection | PubMed |
description | A series of novel ligustrazine derivatives 8a–r were designed, synthesized, and evaluated as multi-targeted inhibitors for anti-Alzheimer’s disease (AD) drug discovery. The results showed that most of them exhibited a potent ability to inhibit both ChEs, with a high selectivity towards AChE. In particular, compounds 8q and 8r had the greatest inhibitory abilities for AChE, with IC(50) values of 1.39 and 0.25 nM, respectively, and the highest selectivity towards AChE (for 8q, IC(50) BuChE/IC(50) AChE = 2.91 × 10(6); for 8r, IC(50) BuChE/IC(50) AChE = 1.32 × 10(7)). Of note, 8q and 8r also presented potent inhibitory activities against Aβ aggregation, with IC(50) values of 17.36 µM and 49.14 µM, respectively. Further cellular experiments demonstrated that the potent compounds 8q and 8r had no obvious cytotoxicity in either HepG2 cells or SH-SY5Y cells, even at a high concentration of 500 μM. Besides, a combined Lineweaver-Burk plot and molecular docking study revealed that these compounds might act as mixed-type inhibitors to exhibit such effects via selectively targeting both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChEs. Taken together, these results suggested that further development of these compounds should be of great interest. |
format | Online Article Text |
id | pubmed-6222487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62224872018-11-13 Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease Wu, Wenhao Liang, Xintong Xie, Guoquan Chen, Langdi Liu, Weixiong Luo, Guolin Zhang, Peiquan Yu, Lihong Zheng, Xuehua Ji, Hong Zhang, Chao Yi, Wei Molecules Article A series of novel ligustrazine derivatives 8a–r were designed, synthesized, and evaluated as multi-targeted inhibitors for anti-Alzheimer’s disease (AD) drug discovery. The results showed that most of them exhibited a potent ability to inhibit both ChEs, with a high selectivity towards AChE. In particular, compounds 8q and 8r had the greatest inhibitory abilities for AChE, with IC(50) values of 1.39 and 0.25 nM, respectively, and the highest selectivity towards AChE (for 8q, IC(50) BuChE/IC(50) AChE = 2.91 × 10(6); for 8r, IC(50) BuChE/IC(50) AChE = 1.32 × 10(7)). Of note, 8q and 8r also presented potent inhibitory activities against Aβ aggregation, with IC(50) values of 17.36 µM and 49.14 µM, respectively. Further cellular experiments demonstrated that the potent compounds 8q and 8r had no obvious cytotoxicity in either HepG2 cells or SH-SY5Y cells, even at a high concentration of 500 μM. Besides, a combined Lineweaver-Burk plot and molecular docking study revealed that these compounds might act as mixed-type inhibitors to exhibit such effects via selectively targeting both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChEs. Taken together, these results suggested that further development of these compounds should be of great interest. MDPI 2018-10-05 /pmc/articles/PMC6222487/ /pubmed/30301153 http://dx.doi.org/10.3390/molecules23102540 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Wenhao Liang, Xintong Xie, Guoquan Chen, Langdi Liu, Weixiong Luo, Guolin Zhang, Peiquan Yu, Lihong Zheng, Xuehua Ji, Hong Zhang, Chao Yi, Wei Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title | Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title_full | Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title_fullStr | Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title_full_unstemmed | Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title_short | Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer’s Disease |
title_sort | synthesis and evaluation of novel ligustrazine derivatives as multi-targeted inhibitors for the treatment of alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222487/ https://www.ncbi.nlm.nih.gov/pubmed/30301153 http://dx.doi.org/10.3390/molecules23102540 |
work_keys_str_mv | AT wuwenhao synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT liangxintong synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT xieguoquan synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT chenlangdi synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT liuweixiong synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT luoguolin synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT zhangpeiquan synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT yulihong synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT zhengxuehua synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT jihong synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT zhangchao synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease AT yiwei synthesisandevaluationofnovelligustrazinederivativesasmultitargetedinhibitorsforthetreatmentofalzheimersdisease |